Novavax Inc. announced on Monday that the company has filed for emergency use authorization of its COVID-19 vaccine with Health Canada, while a the same time finalizing its submission of vaccine data to the European Medicines Agency.
“Novavax continues to deliver regulatory filings that we expect will bring the first protein-based COVID-19 vaccine based on Phase 3 data to the world. We thank the Government of Canada and the European Commission for their ongoing partnership and confidence in our COVID-19 vaccine program,” CEO Stanley Erck noted in the release.
The data noted that the shot offers 100% protection against moderate and severe COVID-19 and 90.4% efficacy overall. Commenting on the outlook, Novavax concluded it would also request vaccine approval in the United States before the end of 2021.
What's happening in Tunisia?
Subscribe to our Youtube channel for updates.
